Adaptation of the Patient Reported Outcome Measurement Information System (PROMIS) tool for childhood cancer in India: A qualitative study

Sasi, Archana; Ganguly, Shuvadeep; Sharma, Shubhangi; Singh, Ritika; Verma, Vishal; Bisht, Reema; Kalra, Devanshi; Satapathy, Sujata; Bakhshi, Sameer

doi:10.1002/pon.6017

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, while vomiting is an objective and measurable phenomenon, nausea assessment in children is challenging, and validated pediatric nausea assessment tools in various socio-cultural settings should be developed and used for improving the nausea assessment among children [89,90]. The objective symptom assessment of cancer and/or supportive care need to be optimized across countries as per their local socio-cultural aspects, and professional guidelines should also incorporate various adaptations in the use of anti-emetics in the local context [91].…”

Section: Discussionmentioning

confidence: 99%

Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting

Ganguly,

Sasi,

Nagaraju

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

The management of chemotherapy-induced nausea and vomiting (CINV) in children remains challenging due to differences in the chemotherapy regimens, their relative emetogenicity compared to that in adults and differences in drug metabolism and the available formulations. The common four classes of anti-emetics used for the treatment and prophylaxis of CINV in children include dexamethasone, neurokinin-1 receptor antagonists, 5-hydroxytryptamine-3 receptor antagonists (5HT3RAs), and olanzapine. The appropriate dose of dexamethasone for CINV prophylaxis in children is unknown, with a significant variability in dosage ranging between 6 and 32 mg/m2/day. The dose of dexamethasone is decreased by 30% when this drug is combined with (fos)aprepitant in children, in contrast to a decrease of 50% required in adults. The use of aprepitant in younger children (<12 years) is often hampered by the non-availability of oral suspension formulations in many countries; alternatively, 80 mg capsules are administered for 1–3 days in certain institutes to children weighing between 15 and 40 kg. Among the different 5HT3RAs, palonosetron is comparatively metabolized faster in children than in adults, requiring a higher dosage for similar efficacy to that achieved in adults. Olanzapine is a newer agent, used in doses between 0.1 and 0.14 mg/kg/day in children, with good anti-emetic efficacy, but has sedation and hyperglycemia as concerning adverse effects. Drug interactions between anti-emetics and between anti-emetics and chemotherapy/supportive agents (azole antifungals, cyclosporine, arsenic trioxide), especially QTc prolongation, should be considered during prescription.

show abstract

Section: Discussionmentioning

confidence: 99%